2型糖尿病合并肾病与PPAR基因相关性研究  

PPAR gene polymorphism in diabetic nephropathy

作　　者：应卫婵 霍晓静 

机构地区：[1]金华市人民医院内分泌科,321000 [2]兰溪市人民医院

出　　处：《浙江医学》2013年第6期435-437,共3页Zhejiang Medical Journal

基　　金：金华市科技卫生项目(2011-3-041)

摘　　要：目的探讨2型糖尿病(T2DM)及糖尿病肾病(DN)与过氧化物酶体增殖物受体γ(PPARγ)基因P12A位点多态性的关系。方法选择DM患者(无并发症者100例),DN患者95例;正常对照(CN)组100例。应用RFLPPCR技术检测PPARγP12A位点多态性,比较组间基因型、等位基因频率及临床变量间的差异。结果(1)DM组及DN组P12A12基因及A12等位基因频率均明显低于CN组(P<0.05);DM组与DN组比较,差异无统计学意义(P>0.05)。(2)携带PA基因型的糖尿病患者24h尿蛋白定量、血β2微球蛋白均低于P12P12基因携带者,差异均有统计学意义(均P<0.05)。结论 PPARγ基因P12A位点多态性与DM及DN发病相关,A12等位基因可能是DN的保护因素。Objective To investigate the relationship between the PPAR-γ2 Pro12Ala polymorphism and diabetic nephropathy. Methods The PPAR-γ2Pro12Ala polymorphism was determined by PCR-RFLP in 95 patients with diabetic nephropathy（DN）, 100 type 2 diabetic patients without complications（DM2） and 100 normal controls（CN）. Results The frequency of Pro12Ala mutation was significantly higher in DM2 and DN groups than that in CN group （P〈0.05）. The 24h-urinary protein and serum 13 2 microglobulin levels in DM2 patients with PA genotype were lower than those with PP genotype （both P〈0.05）. Conclusion PPAR y gene P12A polymorphism may be associated with type 2 diabetes and diabetic nephropathy, the A12 allele may be a protective factors for diabetic nephropathy.

关 键 词：2型糖尿病 糖尿病肾病 过氧化物酶体增殖物受体γ 多态性 限制性片段长度 

分 类 号：R587.2[医药卫生—内分泌]